| Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1 DJ Klionsky, AK Abdel-Aziz, S Abdelfatah, M Abdellatif, A Abdoli, S Abel, ... autophagy 17 (1), 1-382, 2021 | 13673* | 2021 |
| Revised international prognostic scoring system for myelodysplastic syndromes PL Greenberg, H Tuechler, J Schanz, G Sanz, G Garcia-Manero, F Solé, ... Blood, The Journal of the American Society of Hematology 120 (12), 2454-2465, 2012 | 3600 | 2012 |
| Clinical effect of point mutations in myelodysplastic syndromes R Bejar, K Stevenson, O Abdel-Wahab, N Galili, B Nilsson, ... New England Journal of Medicine 364 (26), 2496-2506, 2011 | 2013 | 2011 |
| Mortality after surgery in Europe: a 7 day cohort study RM Pearse, RP Moreno, P Bauer, P Pelosi, P Metnitz, C Spies, B Vallet, ... The Lancet 380 (9847), 1059-1065, 2012 | 1503 | 2012 |
| Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies JPJ Issa, G Garcia-Manero, FJ Giles, R Mannari, D Thomas, S Faderl, ... Blood 103 (5), 1635-1640, 2004 | 1045 | 2004 |
| Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia H Kantarjian, Y Oki, G Garcia-Manero, X Huang, S O'Brien, J Cortes, ... Blood 109 (1), 52-57, 2007 | 1001 | 2007 |
| New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international … J Schanz, H Tüchler, F Solé, M Mallo, E Luno, J Cervera, I Granada, ... Journal of clinical oncology 30 (8), 820-829, 2012 | 879 | 2012 |
| Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia KG Roberts, RD Morin, J Zhang, M Hirst, Y Zhao, X Su, SC Chen, ... Cancer cell 22 (2), 153-166, 2012 | 874 | 2012 |
| Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies O Abdel-Wahab, A Mullally, C Hedvat, G Garcia-Manero, J Patel, ... Blood, The Journal of the American Society of Hematology 114 (1), 144-147, 2009 | 861 | 2009 |
| Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high‐risk myelodysplastic syndrome: predictive prognostic models for outcome H Kantarjian, S O'brien, J Cortes, F Giles, S Faderl, E Jabbour, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2006 | 779 | 2006 |
| Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents H Yang, C Bueso-Ramos, C DiNardo, MR Estecio, M Davanlou, QR Geng, ... Leukemia 28 (6), 1280-1288, 2014 | 752 | 2014 |
| Treatment of Philadelphia chromosome–positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate DA Thomas, S Faderl, J Cortes, S O'Brien, FJ Giles, SM Kornblau, ... Blood 103 (12), 4396-4407, 2004 | 746 | 2004 |
| Chemoimmunotherapy with hyper‐CVAD plus rituximab for the treatment of adult Burkitt and Burkitt‐type lymphoma or acute lymphoblastic leukemia DA Thomas, S Faderl, S O'Brien, C Bueso‐Ramos, J Cortes, ... Cancer 106 (7), 1569-1580, 2006 | 741 | 2006 |
| Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia W Wierda, S O’Brien, S Wen, S Faderl, G Garcia-Manero, D Thomas, ... Journal of clinical oncology 23 (18), 4070-4078, 2005 | 705 | 2005 |
| CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer H Ling, R Spizzo, Y Atlasi, M Nicoloso, M Shimizu, RS Redis, N Nishida, ... Genome research 23 (9), 1446-1461, 2013 | 701 | 2013 |
| TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients R Bejar, A Lord, K Stevenson, M Bar-Natan, A Pérez-Ladaga, J Zaneveld, ... Blood, The Journal of the American Society of Hematology 124 (17), 2705-2712, 2014 | 668 | 2014 |
| Acute myeloid leukemia: current progress and future directions H Kantarjian, T Kadia, C DiNardo, N Daver, G Borthakur, E Jabbour, ... Blood cancer journal 11 (2), 41, 2021 | 629 | 2021 |
| Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System H Kantarjian, S O'Brien, F Ravandi, J Cortes, J Shan, JM Bennett, A List, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2008 | 595 | 2008 |
| Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia G Garcia-Manero, HM Kantarjian, B Sanchez-Gonzalez, H Yang, ... Blood 108 (10), 3271-3279, 2006 | 593 | 2006 |
| Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes R Bejar, KE Stevenson, BA Caughey, O Abdel-Wahab, DP Steensma, ... Journal of clinical oncology 30 (27), 3376-3382, 2012 | 585 | 2012 |
